AIDS-associated Kaposi's sarcoma.

J. O. Kahn, Donald W Northfelt, S. A. Miles

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The underlying degree of immune suppression is an important consideration in the selection of treatment for AIDS-KS. In general, subjects with CD4+ T lymphocytes greater than 500/mm3 require only local therapy unless there is some specific disability caused by the AIDS-KS lesions. Subjects with CD4+ T lymphocytes between 200 and 500/mm3 may respond to recombinant interferon. This therapy is effective in controlling AIDS-KS, can be combined with zidovudine, and has anti-HIV properties. If interferon-alpha with zidovudine is clinically ineffective, systemic chemotherapy may then be required. Subjects with AIDS-KS and CD4+ T lymphocytes less than 200/mm3 should receive PCP prophylaxis, may require systemic chemotherapy, and should be maintained on antiretroviral therapy. Therapy of AIDS-KS is not curative, and a treatment plan of the underlying immune deficiency is essential for planning and implementing rational therapy. AIDS-KS is rarely life threatening but often cosmetically and functionally disabling. Treatment plans remain focused on palliative goals and include reduction of extremity or facial edema, elimination of painful lesions, relief of gastrointestinal disturbances induced by AIDS-KS lesions (including symptoms of outlet obstruction, diarrhea, and rarely blood loss), and reduction of the pulmonary burden of AIDS-KS to improve oxygenation and relieve obstructive pneumonias.

Original languageEnglish (US)
Pages (from-to)261-280
Number of pages20
JournalAIDS clinical review
StatePublished - 1992
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Acquired Immunodeficiency Syndrome
Zidovudine
Therapeutics
T-Lymphocytes
Drug Therapy
Interferon-alpha
Interferons
Diarrhea
Edema
Pneumonia
Extremities
HIV
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kahn, J. O., Northfelt, D. W., & Miles, S. A. (1992). AIDS-associated Kaposi's sarcoma. AIDS clinical review, 261-280.

AIDS-associated Kaposi's sarcoma. / Kahn, J. O.; Northfelt, Donald W; Miles, S. A.

In: AIDS clinical review, 1992, p. 261-280.

Research output: Contribution to journalArticle

Kahn, J. O. ; Northfelt, Donald W ; Miles, S. A. / AIDS-associated Kaposi's sarcoma. In: AIDS clinical review. 1992 ; pp. 261-280.
@article{631b1ffa969c4f9fb2020e9b50b0c762,
title = "AIDS-associated Kaposi's sarcoma.",
abstract = "The underlying degree of immune suppression is an important consideration in the selection of treatment for AIDS-KS. In general, subjects with CD4+ T lymphocytes greater than 500/mm3 require only local therapy unless there is some specific disability caused by the AIDS-KS lesions. Subjects with CD4+ T lymphocytes between 200 and 500/mm3 may respond to recombinant interferon. This therapy is effective in controlling AIDS-KS, can be combined with zidovudine, and has anti-HIV properties. If interferon-alpha with zidovudine is clinically ineffective, systemic chemotherapy may then be required. Subjects with AIDS-KS and CD4+ T lymphocytes less than 200/mm3 should receive PCP prophylaxis, may require systemic chemotherapy, and should be maintained on antiretroviral therapy. Therapy of AIDS-KS is not curative, and a treatment plan of the underlying immune deficiency is essential for planning and implementing rational therapy. AIDS-KS is rarely life threatening but often cosmetically and functionally disabling. Treatment plans remain focused on palliative goals and include reduction of extremity or facial edema, elimination of painful lesions, relief of gastrointestinal disturbances induced by AIDS-KS lesions (including symptoms of outlet obstruction, diarrhea, and rarely blood loss), and reduction of the pulmonary burden of AIDS-KS to improve oxygenation and relieve obstructive pneumonias.",
author = "Kahn, {J. O.} and Northfelt, {Donald W} and Miles, {S. A.}",
year = "1992",
language = "English (US)",
pages = "261--280",
journal = "AIDS clinical review",
issn = "1045-2877",
publisher = "Marcel Dekker Inc.",

}

TY - JOUR

T1 - AIDS-associated Kaposi's sarcoma.

AU - Kahn, J. O.

AU - Northfelt, Donald W

AU - Miles, S. A.

PY - 1992

Y1 - 1992

N2 - The underlying degree of immune suppression is an important consideration in the selection of treatment for AIDS-KS. In general, subjects with CD4+ T lymphocytes greater than 500/mm3 require only local therapy unless there is some specific disability caused by the AIDS-KS lesions. Subjects with CD4+ T lymphocytes between 200 and 500/mm3 may respond to recombinant interferon. This therapy is effective in controlling AIDS-KS, can be combined with zidovudine, and has anti-HIV properties. If interferon-alpha with zidovudine is clinically ineffective, systemic chemotherapy may then be required. Subjects with AIDS-KS and CD4+ T lymphocytes less than 200/mm3 should receive PCP prophylaxis, may require systemic chemotherapy, and should be maintained on antiretroviral therapy. Therapy of AIDS-KS is not curative, and a treatment plan of the underlying immune deficiency is essential for planning and implementing rational therapy. AIDS-KS is rarely life threatening but often cosmetically and functionally disabling. Treatment plans remain focused on palliative goals and include reduction of extremity or facial edema, elimination of painful lesions, relief of gastrointestinal disturbances induced by AIDS-KS lesions (including symptoms of outlet obstruction, diarrhea, and rarely blood loss), and reduction of the pulmonary burden of AIDS-KS to improve oxygenation and relieve obstructive pneumonias.

AB - The underlying degree of immune suppression is an important consideration in the selection of treatment for AIDS-KS. In general, subjects with CD4+ T lymphocytes greater than 500/mm3 require only local therapy unless there is some specific disability caused by the AIDS-KS lesions. Subjects with CD4+ T lymphocytes between 200 and 500/mm3 may respond to recombinant interferon. This therapy is effective in controlling AIDS-KS, can be combined with zidovudine, and has anti-HIV properties. If interferon-alpha with zidovudine is clinically ineffective, systemic chemotherapy may then be required. Subjects with AIDS-KS and CD4+ T lymphocytes less than 200/mm3 should receive PCP prophylaxis, may require systemic chemotherapy, and should be maintained on antiretroviral therapy. Therapy of AIDS-KS is not curative, and a treatment plan of the underlying immune deficiency is essential for planning and implementing rational therapy. AIDS-KS is rarely life threatening but often cosmetically and functionally disabling. Treatment plans remain focused on palliative goals and include reduction of extremity or facial edema, elimination of painful lesions, relief of gastrointestinal disturbances induced by AIDS-KS lesions (including symptoms of outlet obstruction, diarrhea, and rarely blood loss), and reduction of the pulmonary burden of AIDS-KS to improve oxygenation and relieve obstructive pneumonias.

UR - http://www.scopus.com/inward/record.url?scp=0026478457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026478457&partnerID=8YFLogxK

M3 - Article

SP - 261

EP - 280

JO - AIDS clinical review

JF - AIDS clinical review

SN - 1045-2877

ER -